Article

BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators

2021-03-17

Abstract excerpt

Cell cycle regulators are frequently altered in Triple-Negative Breast Cancer (TNBC). Emerging agents targeting these signals offer the possibility to design new combinatorial therapies. However, preclinical models that recapitulate TNBC primary resistance and heterogeneity are essential to evaluate the potency of these combined treatments. <h4>Methods</h4> Bioinformatic processing of human breast cancer datasets...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bbb0a628-1f30-514d-9b14-32d3cca1e9ee
DOI: 10.1101/2021.03.16.435600

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulatorsDOI 10.1101/2021.03.16.435600Read

Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistanceSemantic proximity Read

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistanceSemantic proximity Read

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerSemantic proximity Read

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysSemantic proximity Read

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.Semantic proximity Read

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionSemantic proximity Read

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read

Targeted Therapies for Triple-Negative Breast Cancer.Semantic proximity Read

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read